Niagen Bioscience, Inc. Overview
Pro stress-test →Niagen Bioscience is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research, dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services.
Strategic Profile
Pro stress-test →The company changed its name from ChromaDex to Niagen Bioscience, effective March 19, 2025, with its NASDAQ ticker symbol changing from "CDXC" to "NAGE." The company developed patented Niagen® (nicotinamide riboside, NR), which demonstrates superior efficacy compared to other NAD+ precursors in clinical trials. The company owns and licenses a robust, secure portfolio of over 100 patents covering its flagship Niagen ingredient.
Competitive Landscape
Pro stress-test →With over 25 years of innovation, Niagen Bioscience is positioned as the global leader in NAD+ research and technology, with solutions backed by world-class science, clinical research, and unmatched quality. The NAD+ supplementation market is emerging and growing, with limited direct competitors in pharmaceutical-grade formulations. Key competitive advantages include first-mover status, extensive patent portfolio, and clinical validation.
Industry Context
Niagen Bioscience, Inc. operates in Bioscience / Nutritional Supplement / Healthy Aging.
Key facts
Founded: 1999 · Headquarters: Los Angeles, California · Market cap: $0.51B